SynthesisBMC public health2025
Global prevalence of psittacosis in outbreaks: a systematic review and meta-analysis.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Chlamydia psittaci induces GSDME-mediated pyroptosis via the ROS-JNK signaling pathway.Molecular and cellular biochemistry · 2026Article
- Hearing loss as the initial manifestation ofIDCases · 2026Article
- Systemic inflammation, multi-organ injury, and acute kidney risk in psittacosis pneumonia: a biomarker-driven clinical characterization.Frontiers in cellular and infection microbiology · 2026Article
- Review
- A case of severe psittacosis in a hemodialysis patient-the critical role of detailed medical history and next-generation sequencing.Frontiers in medicine · 2026Article
- Epidemiology of Norovirus Outbreaks in Kindergartens, Primary Schools, and Junior High Schools in Xi'an, China, From October 2020 to February 2023.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Clinical characteristics of Chlamydia psittaci pneumonia: a single-center, retrospective study over 5 years.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPsittacosis is a globally underappreciated and frequently undiagnosed zoonotic disease, and it is often difficult to determine the number of individuals exposed to Chlamydia psittaci. Despite numerous reported cases and outbreaks worldwide, there has been no systematic assessment of psittacosis prevalence to date, which is crucial for evaluating the disease burden and developing vaccines. Our objective is to evaluate the global prevalence of psittacosis in outbreaks.
methodsWe conducted a comprehensive search across multiple databases, including PubMed, Web of Science, Cochrane Library, and Medline, from the date of establishment to May 15, 2024. Additionally, we manually searched reference lists of included articles and retrieved reviews to identify any supplementary articles. The primary summary data was the prevalence of psittacosis in the outbreaks. Pooled estimates of prevalence were calculated for both the entire population and subgroups using a random-effects model.
resultsThirty-one eligible studies from 13 countries across four continents were included in this review. The pooled prevalence of psittacosis among 4,158 exposed individuals in outbreaks was 27.7% (95% CI: 20.9-34.9). Meta-regression analysis of six potential influencing factors (geographic region, outbreak sites, outbreak season, infectious source, publication year, and study quality) indicated that the source of heterogeneity may be associated with the outbreak sites (P = 0.031). Furthermore, among the cases collected, the hospitalization rate was 42.3% (95% CI: 24.7-60.8), the prevalence of pneumonia was 59.7% (95% CI: 41.4-76.9), and the fatality rate was 1.8% (95% CI: 0-6.9).
conclusionsThe global prevalence of psittacosis in outbreaks was found to be 27.7%, with a hospitalization rate of 42.3%, a pneumonia rate of 59.7%, and a mortality rate of 1.8%. Such knowledge will assist governmental and medical authorities in formulating public health policies for populations at high risk of bird exposure, assessing the disease burden, and developing effective vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.